ReviewEuropean journal of haematology2025
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.
Review in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy.Frontiers in immunology · 2026Pooled it
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.ESMO open · 2025Pooled it
- Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.European journal of haematology · 2026Review
- Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.The FEBS journal · 2026Review
- GPCRs in CAR-T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM.European journal of haematology · 2026Review
- Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.Blood advances · 2026Article
- Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.Blood advances · 2026Article
- Pseudoprogression of bladder extramedullary disease of multiple myeloma following the treatment with elranatamab, an anti-BCMA/CD3 bispecific antibody.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- On-target, off-tumor oral toxicities of talquetamab in heavily pretreated multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers.Discover oncology · 2026Review
- Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study.Frontiers in pharmacology · 2026Article
- An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context.Computational and structural biotechnology journal · 2026Review
- Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Vaccination in Multiple Myeloma: Challenges and Strategies.European journal of haematology · 2025Review
- Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.European journal of haematology · 2025Article
- Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.Current obesity reports · 2025Review
- Efficacy and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients.American journal of translational research · 2025Article
- Immunotherapy of osteosarcoma based on immune microenvironment modulation.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those with triple- and penta-refractory disease. Talquetamab, recently approved by the FDA and EMA, is indicated for patients who have progressed after at least three or four prior lines of therapy (LOTs). Administered following a step-up dosing phase to manage cytokine release syndrome (CRS), talquetamab demonstrated a high overall response rate (ORR) of approximately 70%, including in patients previously treated with T-cell redirecting therapies. Its safety profile is consistent with other BsAbs, with hematologic adverse events such as anemia and neutropenia commonly reported, alongside unique on-target off-tumor toxicities like dysgeusia and skin-related events. Infections were less frequent compared to other BsAbs. The optimal sequencing of talquetamab and other therapies, including CAR-T cell treatments, remains an area of active research, as resistance to anti-BCMA therapies presents ongoing clinical challenges. Current trials are exploring the use of talquetamab in combination therapies, as well as therapeutic strategies post-treating progression. The real-world data further support talquetamab's efficacy, making it a valuable addition to the RRMM treatment landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.